Estados Unidos · Prensa financiera · Investor's Business Daily
Travere Is On A Crash Course With Its 200-Day Line — Here's What Happened
Shares of Travere Therapeutics took a hit Tuesday after fewer than expected patients started treatment with its kidney drug, Filspari. The post Travere Is On A Crash Course With…
Leer el artículo completo en Investor's Business Daily Inicie sesión para guardarMarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.investors.com)
